HOME >> BIOLOGY >> NEWS
Clinical trial shows timing of chemotherapy improves survival in breast cancer

New York, December 12, 2002 New research shows that giving doses of chemotherapy more frequently in time, leads to a significant improvement in survival with no increase in toxicity in women with node-positive breast cancer. The study, coordinated by the Cancer and Leukemia Group B (CALGB) for the National Cancer Institute's Breast Intergroup, found a 31 percent decrease in the death rate with more frequent chemotherapy administration, called "dose dense," compared to conventional treatment. The findings will be presented today at the 25th Annual San Antonio Breast Cancer Symposium.

"Since breast cancer is so common, and adjuvant drug therapy has already been found to be so effective, a way to make that treatment 31 percent more effective could potentially save thousands of lives per year in the United States alone," said Larry Norton, MD, Head of the Division of Solid Tumor Oncology at Memorial Sloan-Kettering Cancer Center, and senior author of the study.

A mathematical model called the Norton-Simon hypothesis formed the basis for the concept of dose density and another concept tested in this study, sequential therapy. The model, developed by Dr. Norton, and Richard Simon of the National Cancer Institute, was used to address the question: "Is it better to use a higher dose of a drug less often or a lower dose more frequently?" According to Dr. Norton, the answer depended upon the efficacy of the drugs and the pattern of growth of the disease, and could not be answered without a mathematical understanding of the underlying biology.

The study enrolled 2005 women with primary breast cancer that had spread to the lymph nodes, and with no other metastases. They were randomized post-operatively to one of four treatments. Two groups of patients were randomized to receive doxorubicin (A for Adriamycin), paclitaxel (T for Taxol), and cyclophosphamide (C for Cytoxan) sequentially, i.e., one at a time, in two- or three-week c
'"/>

Contact: Christine Hickey
media@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center
12-Dec-2002


Page: 1 2 3

Related biology news :

1. Creation of the UK Clinical Research Collaboration will boost clinical trials in UK
2. Clinical judgement still counts strongly alongside genetic testing
3. Jay Levy honored with 2004 Abbott Laboratories Award in Clinical and Diagnostic Immunology
4. Melvin Weinstein wins 2004 BD Award for Research in Clinical Microbiology
5. DFG to establish seven new Clinical Research Units
6. Clinical trial patients dont care about study sponsors or physician conflicts of interest
7. NIH establishes Rare Diseases Clinical Research Network
8. Clinical study reports findings of combination therapy with DOXIL
9. Clinical study results published in NEJM show promising data on Antegren (natalizumab)
10. Clinical services must catch up
11. Clinical Advances towards the simplification if HIV therapy: First once-daily dosing results for the HIV protease inhibitor, Agenerase

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/20/2016)... 20, 2016  Synaptics Incorporated (NASDAQ: SYNA ... today announced sampling of S1423, its newest ClearPad ... small screen applications including smartwatches, fitness trackers, and ... and rectangular shapes, as well as thick and ... moisture on screen, while wearing gloves, and supports ...
(Date:1/11/2016)... , Jan. 11, 2016 Synaptics Incorporated ... interface solutions, today announced that its ClearPad ® ... (TDDI) products won two separate categories in the 8 ... Innovator and Best Technology Breakthrough. The Synaptics ® ... a simplified supply chain, thinner devices, brighter displays and ...
(Date:1/7/2016)... Jan. 7, 2016 Various factors have ... products such as biologics and biosimilars. Some of ... healthcare expenditure, growing demand for cost-effective alternatives, growing ... Biosimilars are similar versions of their corresponding patented ... their quality, safety, and efficacy. The global biosimilars ...
Breaking Biology News(10 mins):
(Date:2/5/2016)... , Feb. 5, 2016  In the pharmaceutical ... for a host of launch activities including the identification ... this launch activity is especially high in the oncology ... Best Practices and the Role of Medical Affairs ... companies focused on oncology therapies find better ways to ...
(Date:2/4/2016)... CA (PRWEB) , ... February 04, 2016 , ... ... enterprise talent development and compliance training, today announced an interactive FDA compliance ... Playbook™. The RAPS (Regulatory Affairs Professional Society) accredited interactive course on Morf ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... Club, takes place February 5-6 at the University’s student center, Kehr Union, ... such as workshops and competitions for ample networking, learning and collaborating opportunities. ...
(Date:2/4/2016)... -- --> --> Q ... to provide the following update on recent corporate developments. ... 3 months we have significantly increased our cash position through ... a result, we have positioned ourselves to execute on the ... expect that development to continue on schedule. ...
Breaking Biology Technology:
Cached News: